A practical discussion on effective AI adoption in regulated MedTech environments.
he FDA is rolling out internal generative AI tools. The EU AI Act is reshaping discussions around governance and accountability. Meanwhile, RA teams are facing growing MDR workloads, increasing global complexity, and pressure to reduce submission timelines. This webinar explores what all of that means for MedTech companies today.
AI is developing at an incredible pace. But inside regulated environments, speed alone is not enough. The real challenge is understanding where AI can create value, where it introduces risk, and how teams can implement it effectively within existing regulatory frameworks.
- Why Generic AI Tools Fail in Regulated Environments
Many organizations are experimenting with AI, but generic tools often struggle when applied to regulated workflows.
Topics include:
- source validation
- hallucinations and unreliable outputs
- lack of traceability and auditability
- limited regulatory context
- data privacy concerns
2. From Chatbots to Agents to Specialized AI
Understanding the evolution from generic AI chat tools toward specialized AI agents designed for highly regulated regulatory workflows.
3. Practical Steps for Implementing AI in MedTech
The question is no longer whether AI can support RA workflows, but how to implement it effectively.
Topics include:
- identifying high-value use cases while managing risk
- adapting existing workflows to maximize value
- understanding the role of human review in AI-assisted workflows
- setting up review and approval checkpoints for AI-generated outputs
- documentation, traceability, and validation considerations
- risks associated with AI-generated content
- how teams can begin implementing AI effectively
Whether your organization is actively exploring AI or still evaluating where it fits, this session is designed to give regulatory professionals a clearer view of the challenges, expectations, and practical realities shaping AI adoption across MedTech.
